Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

What Was Tested

The paper reports a study of NAD+, published as a randomized controlled trial.

The researchers sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, men only.

Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the NAD+ group and the comparison group should start out alike.

As a double-blind NAD+ study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of NAD+, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Fasting plasma concentrations of bile acids were determined.

What Was Measured

PubMed files the paper under topics including Blood Glucose, C-Peptide, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose Tolerance Test and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of NAD+.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the NAD+ compound page, all human trials.